Xilis is developing a rapid and scalable patient-derived miniature-organoid technology platform to revolutionize precision medicine and pharmaceutical drug discovery. Our micro-organospheres lead to 30x speed, 50x throughput, and 300x cost savings compared to organoids. They remove barriers to conventional organoids going from predictive, accurate research tools to actual clinical practice, and provide unequaled potential for large-scale pharmacogenomic studies representative of the breadth of human genetic diversity during pre-clinical development.